DC Judge Calls Teva's Bid To Reclassify Drug Anticompetitive

By Julia Arciga (January 4, 2021, 10:26 PM EST) -- A D.C. federal court has shot down Teva Pharmaceutical's lawsuit against the U.S. Food and Drug Administration and the Department of Health and Human Services to get its multiple sclerosis drug Copaxone reclassified from a "drug" to a "biological product," calling the suit "yet another effort" by the company to "stifle Copaxone competitors."

In a Thursday decision, U.S. District Chief Judge Beryl A. Howell wrote that the company's claims against the FDA over its definition of "protein" in classifying an item as a "biological product" were unfounded. If Copaxone were to obtain such a classification, it would be significantly harder for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!